C3L-02619
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 70.17932923
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-02285 | — | cohortSQ1 | 0.804 |
| 2 | SRR8613770 | — | E | 0.797 |
| 3 | SRR35579835 | — | C | 0.797 |
| 4 | s0112232 | — | — | 0.787 |
| 5 | 82992 | EPN | Supratentorial EPN | 0.787 |
| 6 | SJEPD004_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.773 |
| 7 | GSM6454752 | — | E | 0.767 |
| 8 | TCGA-98-A539-01A-31R-A262-07 | — | cohortSQ1 | 0.766 |
| 9 | SRR9879274 | — | cohortSQ1 | 0.753 |
| 10 | C3L-02127 | — | cohortSQ2 | 0.752 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| HYPOXIA | 0.370 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.360 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.360 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.330 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.280 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.270 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.260 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.220 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.190 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.180 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |